Precision Medicine

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

An AI firm known for fighting cancer is now partnering with Unilever, signaling a new era of biologically personalized consumer products and new ethical questions.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As oral GLP-1s enter the market, companies offer digital coaching to boost drug efficacy and justify soaring costs for employers and health plans.

The world's top beauty event returns to Paris, showcasing a major shift as ingestible ingredients and holistic wellness redefine the personal care industry.

A 2.5-year-old's sudden paralysis led to a high-risk, pioneering neuro-intervention that reversed a severe stroke, setting a new benchmark for pediatric care.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.

A new national agreement gives thousands of U.S. hospitals streamlined access to Nanosonics' trophon3, aiming to elevate patient safety standards.

As SAB Biotherapeutics prepares for key investor talks, a closer look reveals its novel T1D therapy and the unique bovine tech aiming to change treatment.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

Lantheus gains FDA tentative approval for a LUTATHERA rival, signaling new hope for rare cancer patients and a legal battle with Novartis over market access.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

The FDA has greenlit Ascendis Pharma's once-weekly YUVIWEL for achondroplasia, a major step for patients that also carries significant business implications.

Born from a Novartis mega-deal, Atrium Therapeutics aims its novel RNA platform at rare, untreatable genetic heart diseases. Will its strategy succeed?